With the recent tendency of drug developers to outsource their formulation development services, many CDMOs have adapted to this increased demand by providing innovative biologics development and manufacturing offerings in order to address the multitude of challenges that have arisen.
In this article, Genezen details its plan to build a new cGMP-compliant lentiviral vector production facility as part of a more expansive plan to build a larger 75,000 sq. ft site. The site will include multiple cGMP production suites as well as a full suite of process development capabilities to support cGMP and commercial readiness, which is elaborated upon within the article.
